Table 2.
Interferon-γ in therapy against HIV/AIDS.
| Descriptiona | IFNγ activity or response | Reference |
|---|---|---|
| IFNγ therapy against HIV/AIDS | No effect on HIV load, CD4+ T cell count, and disease progression | (53–57) |
| Adjunctive IFNγ therapy for opportunistic infection | Decreasing trend to significant decrease in opportunistic infection | (61–67) |
| IFNγ levels during ART | ||
| Serum IFNγ levels | ||
| Cross-sectional study | Decreasing trend in serum IFNγ | (20) |
| Longitudinal study | Significant decrease in serum IFNγ | (20) |
| T cell responses | ||
| CD4+ T cells | Varying IFNγ responses | (68–70) |
| CD8+ T cells | Generally decreasing IFNγ response | (70, 71) |
| Polyfunctional CD8+ T cells | Gradual increase in IFNγ response with prolonged ART | (71) |
aChronically HIV-1 infected subjects.